TNF polymorphisms and prostate cancer risk

Kim N. Danforth, Carmen Rodriguez, Richard B. Hayes, Lori C. Sakoda, Wen Yi Huang, Kai Yu, Eugenia E. Calle, Eric J. Jacobs, Bingshu E. Chen, Gerald L. Andriole, Jonine D. Figueroa, Meredith Yeager, Elizabeth A Platz, Dominique S. Michaud, Stephen J. Chanock, Michael J. Thun, Ann W. Hsing

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Inflammation has been hypothesized to increase prostate cancer risk. Tumor necrosis factor (TNF) is an important mediator of the inflammatory process, but the relationship between TNF variants and prostate cancer remains unclear. METHODS. We examined associations between six TNF single nucleotide polymorphisms (SNPs) (rs1799964, rs1800630, rs1799724, rs1800629, rs361525, rs1800610) and prostate cancer risk among 2,321 cases and 2,560 controls from two nested case-control studies within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, n = 2,561, 5 SNPs) and the Cancer Prevention Study II Nutrition Cohort (Nutrition Cohort, n = 2,320, 6 SNPs). Odds ratios and 95% confidence intervals were estimated for individual SNPs and haplotypes in each cohort separately and in pooled analyses. RESULTS. No TNF SNP was associated with prostate cancer risk in PLCO (P-trend ≥ 0.16), while in the Nutrition Cohort, associations were significant for 2 highly correlated variants (rs1799724, 1800610, r2 = 0.95; P-trend = 0.04 and 0.02, respectively). In pooled analyses, no single SNP was associated with prostate cancer risk (P-trend ≥ 0.08). After adjustment for multiple testing, no SNP was associated with prostate cancer risk in either cohort individually or in the pooled analysis (P-trend all ≥ 0.10). Haplotypes based on 5 TNF SNPs did not vary by case/control status in PLCO, but showed marginal associations in the Nutrition Cohort (global P = 0.06) and the pooled analysis (global P = 0.05). CONCLUSIONS. Despite somewhat suggestive haplotype results, overall our study does not support an association between TNF variants and prostate cancer risk.

Original languageEnglish (US)
Pages (from-to)400-407
Number of pages8
JournalProstate
Volume68
Issue number4
DOIs
StatePublished - Mar 1 2008

Fingerprint

Single Nucleotide Polymorphism
Prostatic Neoplasms
Tumor Necrosis Factor-alpha
Haplotypes
Early Detection of Cancer
Ovarian Neoplasms
Case-Control Studies
Colorectal Neoplasms
Lung Neoplasms
Odds Ratio
Confidence Intervals
Inflammation
Neoplasms

Keywords

  • Genetic susceptibility
  • Inflammation
  • Prostate cancer
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Urology

Cite this

Danforth, K. N., Rodriguez, C., Hayes, R. B., Sakoda, L. C., Huang, W. Y., Yu, K., ... Hsing, A. W. (2008). TNF polymorphisms and prostate cancer risk. Prostate, 68(4), 400-407. https://doi.org/10.1002/pros.20694

TNF polymorphisms and prostate cancer risk. / Danforth, Kim N.; Rodriguez, Carmen; Hayes, Richard B.; Sakoda, Lori C.; Huang, Wen Yi; Yu, Kai; Calle, Eugenia E.; Jacobs, Eric J.; Chen, Bingshu E.; Andriole, Gerald L.; Figueroa, Jonine D.; Yeager, Meredith; Platz, Elizabeth A; Michaud, Dominique S.; Chanock, Stephen J.; Thun, Michael J.; Hsing, Ann W.

In: Prostate, Vol. 68, No. 4, 01.03.2008, p. 400-407.

Research output: Contribution to journalArticle

Danforth, KN, Rodriguez, C, Hayes, RB, Sakoda, LC, Huang, WY, Yu, K, Calle, EE, Jacobs, EJ, Chen, BE, Andriole, GL, Figueroa, JD, Yeager, M, Platz, EA, Michaud, DS, Chanock, SJ, Thun, MJ & Hsing, AW 2008, 'TNF polymorphisms and prostate cancer risk', Prostate, vol. 68, no. 4, pp. 400-407. https://doi.org/10.1002/pros.20694
Danforth KN, Rodriguez C, Hayes RB, Sakoda LC, Huang WY, Yu K et al. TNF polymorphisms and prostate cancer risk. Prostate. 2008 Mar 1;68(4):400-407. https://doi.org/10.1002/pros.20694
Danforth, Kim N. ; Rodriguez, Carmen ; Hayes, Richard B. ; Sakoda, Lori C. ; Huang, Wen Yi ; Yu, Kai ; Calle, Eugenia E. ; Jacobs, Eric J. ; Chen, Bingshu E. ; Andriole, Gerald L. ; Figueroa, Jonine D. ; Yeager, Meredith ; Platz, Elizabeth A ; Michaud, Dominique S. ; Chanock, Stephen J. ; Thun, Michael J. ; Hsing, Ann W. / TNF polymorphisms and prostate cancer risk. In: Prostate. 2008 ; Vol. 68, No. 4. pp. 400-407.
@article{887338f3548f4dd392656691e8cfa6b9,
title = "TNF polymorphisms and prostate cancer risk",
abstract = "BACKGROUND. Inflammation has been hypothesized to increase prostate cancer risk. Tumor necrosis factor (TNF) is an important mediator of the inflammatory process, but the relationship between TNF variants and prostate cancer remains unclear. METHODS. We examined associations between six TNF single nucleotide polymorphisms (SNPs) (rs1799964, rs1800630, rs1799724, rs1800629, rs361525, rs1800610) and prostate cancer risk among 2,321 cases and 2,560 controls from two nested case-control studies within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, n = 2,561, 5 SNPs) and the Cancer Prevention Study II Nutrition Cohort (Nutrition Cohort, n = 2,320, 6 SNPs). Odds ratios and 95{\%} confidence intervals were estimated for individual SNPs and haplotypes in each cohort separately and in pooled analyses. RESULTS. No TNF SNP was associated with prostate cancer risk in PLCO (P-trend ≥ 0.16), while in the Nutrition Cohort, associations were significant for 2 highly correlated variants (rs1799724, 1800610, r2 = 0.95; P-trend = 0.04 and 0.02, respectively). In pooled analyses, no single SNP was associated with prostate cancer risk (P-trend ≥ 0.08). After adjustment for multiple testing, no SNP was associated with prostate cancer risk in either cohort individually or in the pooled analysis (P-trend all ≥ 0.10). Haplotypes based on 5 TNF SNPs did not vary by case/control status in PLCO, but showed marginal associations in the Nutrition Cohort (global P = 0.06) and the pooled analysis (global P = 0.05). CONCLUSIONS. Despite somewhat suggestive haplotype results, overall our study does not support an association between TNF variants and prostate cancer risk.",
keywords = "Genetic susceptibility, Inflammation, Prostate cancer, Tumor necrosis factor",
author = "Danforth, {Kim N.} and Carmen Rodriguez and Hayes, {Richard B.} and Sakoda, {Lori C.} and Huang, {Wen Yi} and Kai Yu and Calle, {Eugenia E.} and Jacobs, {Eric J.} and Chen, {Bingshu E.} and Andriole, {Gerald L.} and Figueroa, {Jonine D.} and Meredith Yeager and Platz, {Elizabeth A} and Michaud, {Dominique S.} and Chanock, {Stephen J.} and Thun, {Michael J.} and Hsing, {Ann W.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1002/pros.20694",
language = "English (US)",
volume = "68",
pages = "400--407",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - TNF polymorphisms and prostate cancer risk

AU - Danforth, Kim N.

AU - Rodriguez, Carmen

AU - Hayes, Richard B.

AU - Sakoda, Lori C.

AU - Huang, Wen Yi

AU - Yu, Kai

AU - Calle, Eugenia E.

AU - Jacobs, Eric J.

AU - Chen, Bingshu E.

AU - Andriole, Gerald L.

AU - Figueroa, Jonine D.

AU - Yeager, Meredith

AU - Platz, Elizabeth A

AU - Michaud, Dominique S.

AU - Chanock, Stephen J.

AU - Thun, Michael J.

AU - Hsing, Ann W.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - BACKGROUND. Inflammation has been hypothesized to increase prostate cancer risk. Tumor necrosis factor (TNF) is an important mediator of the inflammatory process, but the relationship between TNF variants and prostate cancer remains unclear. METHODS. We examined associations between six TNF single nucleotide polymorphisms (SNPs) (rs1799964, rs1800630, rs1799724, rs1800629, rs361525, rs1800610) and prostate cancer risk among 2,321 cases and 2,560 controls from two nested case-control studies within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, n = 2,561, 5 SNPs) and the Cancer Prevention Study II Nutrition Cohort (Nutrition Cohort, n = 2,320, 6 SNPs). Odds ratios and 95% confidence intervals were estimated for individual SNPs and haplotypes in each cohort separately and in pooled analyses. RESULTS. No TNF SNP was associated with prostate cancer risk in PLCO (P-trend ≥ 0.16), while in the Nutrition Cohort, associations were significant for 2 highly correlated variants (rs1799724, 1800610, r2 = 0.95; P-trend = 0.04 and 0.02, respectively). In pooled analyses, no single SNP was associated with prostate cancer risk (P-trend ≥ 0.08). After adjustment for multiple testing, no SNP was associated with prostate cancer risk in either cohort individually or in the pooled analysis (P-trend all ≥ 0.10). Haplotypes based on 5 TNF SNPs did not vary by case/control status in PLCO, but showed marginal associations in the Nutrition Cohort (global P = 0.06) and the pooled analysis (global P = 0.05). CONCLUSIONS. Despite somewhat suggestive haplotype results, overall our study does not support an association between TNF variants and prostate cancer risk.

AB - BACKGROUND. Inflammation has been hypothesized to increase prostate cancer risk. Tumor necrosis factor (TNF) is an important mediator of the inflammatory process, but the relationship between TNF variants and prostate cancer remains unclear. METHODS. We examined associations between six TNF single nucleotide polymorphisms (SNPs) (rs1799964, rs1800630, rs1799724, rs1800629, rs361525, rs1800610) and prostate cancer risk among 2,321 cases and 2,560 controls from two nested case-control studies within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, n = 2,561, 5 SNPs) and the Cancer Prevention Study II Nutrition Cohort (Nutrition Cohort, n = 2,320, 6 SNPs). Odds ratios and 95% confidence intervals were estimated for individual SNPs and haplotypes in each cohort separately and in pooled analyses. RESULTS. No TNF SNP was associated with prostate cancer risk in PLCO (P-trend ≥ 0.16), while in the Nutrition Cohort, associations were significant for 2 highly correlated variants (rs1799724, 1800610, r2 = 0.95; P-trend = 0.04 and 0.02, respectively). In pooled analyses, no single SNP was associated with prostate cancer risk (P-trend ≥ 0.08). After adjustment for multiple testing, no SNP was associated with prostate cancer risk in either cohort individually or in the pooled analysis (P-trend all ≥ 0.10). Haplotypes based on 5 TNF SNPs did not vary by case/control status in PLCO, but showed marginal associations in the Nutrition Cohort (global P = 0.06) and the pooled analysis (global P = 0.05). CONCLUSIONS. Despite somewhat suggestive haplotype results, overall our study does not support an association between TNF variants and prostate cancer risk.

KW - Genetic susceptibility

KW - Inflammation

KW - Prostate cancer

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=40349116159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40349116159&partnerID=8YFLogxK

U2 - 10.1002/pros.20694

DO - 10.1002/pros.20694

M3 - Article

C2 - 18196539

AN - SCOPUS:40349116159

VL - 68

SP - 400

EP - 407

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -